Abstract |
Acyclic retinoid (all-trans-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) has a slightly different structure from all-trans retinoic acid (ATRA), while it binds cellular retinoic acid- binding protein with a similar binding affinity to that of ATRA. We studied the in vitro efficacy of acyclic retinoid for the differentiation induction of human promyelocyte-derived HL-60 cell line and primary cultured blast cells obtained from 8 patients with acute non- lymphocytic leukemia ( ANLL) including 3 acute promyelocytic leukemia (APL) patients. HL-60 cells and ANLL cells were incubated with or without retinoids for 5 days. Acyclic retinoid induced the differentiation of HL-60 cells and APL cells at 10(-6) mol/l, while ATRA induced differentiation at 10(-7) mol/l. These concentrations were well below those that affected cell growth and viability. Although ATRA has an excellent capacity for differentiation induction of HL-60 and APL cells, it is also known to have severe, sometimes fatal, adverse effects, including retinoic acid syndrome. In contrast, acyclic retinoid is reported to have a much wider safety margin than that of ATRA. A clinical trial of acyclic retinoid for the differentiation induction therapy of APL may be worthwhile.
|
Authors | H Tsurumi, A Tojo, T Takahashi, K Ozawa, H Moriwaki, S Asano, Y Muto |
Journal | International journal of hematology
(Int J Hematol)
Vol. 59
Issue 1
Pg. 9-15
(Dec 1993)
ISSN: 0925-5710 [Print] Japan |
PMID | 8161738
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Tretinoin
- 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid
|
Topics |
- Adolescent
- Adult
- Cell Differentiation
(drug effects)
- Female
- Humans
- Leukemia, Promyelocytic, Acute
(pathology)
- Male
- Middle Aged
- Tretinoin
(analogs & derivatives, pharmacology)
- Tumor Cells, Cultured
|